What Is Survodutide? Why It Matters for Both Obesity and MASH

What is Survodutide?

Survodutide is an investigational once-weekly injectable that combines GLP-1 receptor agonism with glucagon receptor agonism. It is being developed by Boehringer Ingelheim and Zealand Pharma.

The dual GLP-1/glucagon mechanism is significant because glucagon signaling contributes to energy expenditure and hepatic lipid metabolism—the biological rationale underpinning survodutide’s development in both obesity and liver disease. This places survodutide closer to the GLP-1/glucagon axis of the obesity pipeline than to amylin-based agents such as CagriSema or petrelintide. For a head-to-head comparison with the leading triple agonist, see our survodutide vs retatrutide analysis. Another notable dual-agonist in clinical development is mazdutide (IBI362), which targets the same GLP-1/glucagon receptor pathways.

How Survodutide Activates Glucagon and GLP-1 Receptors

Survodutide’s mechanism centres on simultaneous activation of the glucagon like peptide 1 (GLP-1) receptor and the glucagon receptor. The GLP-1 receptor mediates appetite suppression, insulin secretion, and gastric emptying—effects well established by approved GLP-1 receptor agonist therapies including once weekly semaglutide and tirzepatide. What distinguishes survodutide as a dual agonist is the addition of a novel glucagon receptor signaling pathway that promotes hepatic lipid oxidation and energy expenditure.

Glucagon Like Peptide 1 and Energy Balance

Glucagon like peptide 1 is an incretin hormone released from intestinal L-cells in response to nutrient intake. Activation of the GLP-1 receptor reduces food intake through central appetite suppression and peripheral metabolic effects. Pure GLP-1 receptor agonist drugs leverage this pathway exclusively, whereas survodutide combines glucagon and GLP-1 receptor activation for a broad spectrum approach to the treatment of obesity. The dual engagement of glucagon and GLP-1 signaling may produce additive or synergistic effects on body weight reduction compared with placebo and compared to GLP-1 receptor agonism alone.

Subcutaneous Survodutide: Dosing and Administration

Subcutaneous survodutide is administered as a once-weekly injection using a prefilled device. The subcutaneous route allows for sustained drug exposure throughout the dosing interval, supporting consistent GLP-1 receptor and glucagon receptor engagement. Subcutaneous survodutide dose escalation protocols in clinical trials were designed to mitigate gastrointestinal adverse events during initiation, similar to the approach used with other GLP-1 receptor agonist therapies in the treatment of obesity.

Phase 2 Trial Design & Methodology

The pivotal Phase 2 obesity study for survodutide was a randomised, double blind, placebo controlled trial evaluating multiple dose levels in adults with overweight or obesity. The controlled trial enrolled participants with a body mass index (BMI) ≥30 kg/m² or ≥27 kg/m² with at least one weight-related comorbidity. Baseline characteristics included mean body weight of approximately 105 kg and mean body mass index of approximately 37 kg/m², consistent with other Phase 2 obesity trials in the incretin field.

Randomised and treated participants received once-weekly subcutaneous injections of survodutide at escalating dose levels or placebo for up to 46 weeks. The double blind placebo controlled design ensured neither investigators nor participants knew treatment assignment, with interactive response technology used for randomisation and drug supply management. The clinical trial steering committee provided ongoing oversight of safety and protocol adherence throughout the study.

What Are Survodutide’s Obesity Trial Results?

Zealand’s pipeline materials report that survodutide demonstrated weight loss of up to 18.7% after 46 weeks in Phase 2 obesity studies. That figure places survodutide among the strongest investigational obesity datasets currently in the pipeline. For the latest regulatory timeline, see our page on whether survodutide is approved yet.

The current official status: Boehringer Ingelheim is evaluating survodutide in global Phase 3 trials for people living with overweight and obesity. Phase 3 obesity results have not yet been reported. For context on where survodutide sits in the broader pipeline, see our best research peptides guide for 2026.

Body Weight & BMI Outcomes by Dose

Survodutide produced dose-dependent bodyweight reductions across all active treatment groups in the Phase 2 trial. The dose response effects were clear: higher doses of survodutide resulted in greater body weight reduction, with the highest dose group achieving mean body weight loss of 18.7% at 46 weeks compared to approximately 2% in the placebo arm. Absolute body weight reductions exceeded 15 kg at the top dose level.

Mean body mass index decreased by approximately 7 points in the highest-dose group, shifting a substantial proportion of participants from obesity class II or III into lower BMI categories. These body weight reduction outcomes compare favourably with other dual agonists in development. Results from the Phase 2 trial were published in Diabetes, Obesity and Metabolism (Diabetes Obes Metab), confirming survodutide’s position as a leading candidate in the treatment of obesity.

Waist Circumference and Body Composition Data

In the Phase 2 trial, survodutide compared with placebo demonstrated significant reductions in waist circumference across all active dose groups. The percentage change in waist circumference from baseline was dose-dependent, with the highest dose group achieving the greatest relative change. Waist circumference is an important clinical marker because it reflects visceral adiposity, which is independently associated with cardiovascular risk and metabolic dysfunction.

Percentage Change and Relative Change in Endpoints

Primary and secondary endpoints in the Phase 2 trial were reported as percentage change from baseline in body weight. The relative change in body weight at the top dose level—18.7% at 46 weeks—survodutide compared with placebo established the compound’s position in the competitive dual agonist landscape. Additional endpoints including relative change in waist circumference, fasting glucose, and HbA1c were also assessed in randomized and treated participants. Baseline characteristics of treated participants were balanced across treatment arms, supporting the validity of between-group comparisons. The relative change data were published with full access to supplementary materials.

Safety Profile & Adverse Events

The safety analysis of the Phase 2 trial showed that adverse events were predominantly gastrointestinal in nature, consistent with the GLP-1 receptor agonist class. The most commonly reported adverse events included nausea, diarrhea, and vomiting, with incidence rates that increased with dose. Most GI adverse events were mild to moderate in severity and occurred primarily during the dose-escalation phase.

Serious adverse events were infrequent and balanced across treatment groups. Discontinuation rates due to adverse events were low overall but higher at the top dose level. The safety analysis did not reveal unexpected safety signals beyond the known GLP-1 class effects. Long-term safety data from the Phase 3 LIVERAGE and obesity programmes will provide a more comprehensive adverse events profile.

Cardiovascular & Metabolic Effects

Survodutide demonstrated improvements in several cardiometabolic risk factors in Phase 2 data. Reductions in systolic blood pressure and diastolic blood pressure were observed across dose groups, consistent with the cardiovascular benefits expected from substantial body weight reduction. Lipid parameters including LDL cholesterol and triglycerides also improved.

These cardiovascular outcomes are particularly relevant given that obesity is a major risk factor for cardiovascular disease, coronary artery disease, and heart failure. Research from the Cardiovascular Research Institute and other institutions has highlighted the importance of weight-loss interventions in reducing cardiovascular outcomes burden. Boehringer Ingelheim has indicated that cardiovascular outcomes assessments will be incorporated into the Phase 3 programme, reflecting the growing regulatory expectation that obesity drugs demonstrate cardiovascular benefit alongside body weight reduction.

SYNCHRONIZE CVOT: Survodutide’s Cardiovascular Outcomes Trial

Boehringer Ingelheim International GmbH has initiated the SYNCHRONIZE CVOT (cardiovascular outcomes trial) to evaluate the cardiometabolic effects of survodutide in patients with established cardiovascular disease and obesity. The SYNCHRONIZE CVOT is one of the largest cardiovascular outcomes trials in the obesity drug development landscape, reflecting the growing regulatory expectation that weight-loss therapies demonstrate cardiovascular safety and potential cardiovascular benefit. The SYNCHRONIZE CVOT enrolled patients with increased CV risk, including those with prior myocardial infarction, prevalent heart failure, and atrial fibrillation.

SYNCHRONIZE CVOT Enrollment Criteria

The SYNCHRONIZE CVOT enrolled adults with overweight or obesity and established atherosclerotic cardiovascular disease or multiple cardiovascular risk factors. Key inclusion criteria for the SYNCHRONIZE CVOT included prior myocardial infarction, history of stroke or peripheral arterial disease, prevalent heart failure (NYHA class II–III), and atrial fibrillation. Patients across CKD risk categories were also eligible for enrollment in the SYNCHRONIZE CVOT, provided they met the cardiovascular entry criteria. Baseline characteristics of SYNCHRONIZE CVOT treated participants included mean body weight, body mass index, and cardiometabolic parameters. Boehringer Ingelheim Pharma GmbH coordinates the clinical operations for the SYNCHRONIZE CVOT across multiple global sites.

Heart Failure Endpoints in SYNCHRONIZE CVOT

Heart failure is a pre-specified endpoint category within the SYNCHRONIZE CVOT programme. The trial assesses heart failure hospitalization, heart failure exacerbation, and composite cardiovascular outcomes including cardiovascular death and heart failure events. The Kansas City Cardiomyopathy Questionnaire is used within the SYNCHRONIZE CVOT to assess patient-reported heart failure outcomes, including heart failure symptom burden and functional status. Heart failure with preserved ejection fraction (HFpEF) is of particular interest given the emerging data linking the treatment of obesity with improved heart failure outcomes.

Cardiovascular Risk and Increased CV Risk Subgroups

Pre-specified subgroup analyses in the SYNCHRONIZE CVOT will examine outcomes in patients with increased CV risk, including those with prevalent heart failure, atrial fibrillation, and chronic kidney disease across CKD risk categories. Kansas City Cardiomyopathy Questionnaire scores at baseline and at pre-specified timepoints will be used to assess heart failure trajectory. The SYNCHRONIZE CVOT is expected to report primary results in 2028–2029, providing cardiovascular outcomes data that could differentiate survodutide from competitors. Boehringer Ingelheim International GmbH has committed to the SYNCHRONIZE CVOT as part of a comprehensive development strategy for survodutide in the treatment of obesity and cardiometabolic disease.

Why Is Survodutide Being Developed for MASH?

MASH (metabolic dysfunction-associated steatohepatitis) is one of the most important adjacent metabolic conditions. Many patients with obesity also have progressive fatty liver disease and associated fibrosis risk. A compound that can compete in both obesity and MASH attracts significantly more strategic attention than one confined to a single indication. For a comparison of the leading injectable candidates, see our retatrutide vs tirzepatide vs CagriSema analysis.

Zealand announced that the FDA granted Breakthrough Therapy designation for survodutide in MASH, and that two Phase 3 trials were initiated in October 2024.

Obesity Management & Long-Term Considerations

One of the critical challenges in the treatment of obesity is weight regain after discontinuation of pharmacotherapy. While survodutide’s Phase 2 data demonstrated substantial body weight reduction during active treatment, the durability of weight management effects following cessation remains an open question. Weight regain has been observed with other GLP-1-based obesity medications upon treatment withdrawal, and long-term obesity management strategies may require sustained pharmacotherapy.

Survodutide’s dual glucagon receptor agonism may offer theoretical advantages for long-term weight management through enhanced energy expenditure—a metabolic pathway not meaningfully engaged by pure GLP-1 agonists. Whether this translates into reduced weight regain or improved outcomes in metabolic comorbidities such as chronic kidney disease and obstructive sleep apnoea will be clarified by the ongoing Phase 3 programme. The broader shift toward viewing obesity as a chronic condition requiring sustained obesity management has accelerated development timelines across the incretin pipeline.

Key Research Publications and Evidence Base

Survodutide’s clinical data have been published in leading medical journals. Phase 2 obesity results appeared in Diabetes Obes Metab (Diabetes, Obesity and Metabolism), establishing the dose-response relationship and tolerability profile. The N Engl J Med (New England Journal of Medicine) has published key incretin and obesity trial results that provide context for survodutide’s position in the treatment of obesity. Investigators from Harvard Medical School and Brigham and Women’s Hospital have contributed to the broader evidence base for GLP-1 receptor agonist and dual agonist therapies, with several authors having received research support from Boehringer Ingelheim International GmbH.

Journal Publications and Disclosures

Research published in N Engl J Med, Lancet Diabetes Endocrinol, and Diabetes Obes Metab has shaped the clinical understanding of dual agonist approaches in obesity. Authors from Brigham and Women’s Hospital and Harvard Medical School who have published on glucagon like peptide 1 receptor agonist therapies have disclosed received research support from pharmaceutical sponsors including Boehringer Ingelheim Pharma GmbH. Position statement documents from medical societies have referenced N Engl J Med publications and Lancet Diabetes Endocrinol data when evaluating the evidence for novel obesity pharmacotherapies.

Parallel Group Design and Trial Methodology

The Phase 2 survodutide trial used a parallel group, randomised, double-blind, placebo-controlled design. Each parallel group received a fixed dose of subcutaneous survodutide or matching placebo. Baseline characteristics—including body weight, body mass index, waist circumference, and cardiometabolic parameters—were balanced across parallel group assignments. All treated participants provided informed consent and were followed through the complete treatment period. Results were published with full access to supplementary data in Diabetes Obes Metab, with search terms and methodology documented per CONSORT guidelines. N Engl J Med and Lancet Diabetes Endocrinol have also published related research support for the dual agonist treatment of obesity.

Competitive Landscape: Additional Targets in Obesity

Survodutide competes in a rapidly expanding obesity drug pipeline with compounds targeting additional targets beyond the GLP-1 receptor. Structure Therapeutics is developing oral small-molecule GLP-1 receptor agonists that could offer broad spectrum access to the treatment of obesity without injectable administration. GI Dynamics has pursued device-based approaches to weight management, while integrated healthcare providers such as Optum Health are expanding obesity management programmes that incorporate both pharmacotherapy and behavioral interventions.

Regional Development and Global Trials

Boehringer Ingelheim International GmbH coordinates survodutide’s global clinical trial programme from its headquarters, with Boehringer Ingelheim Pharma GmbH managing manufacturing and drug supply. Clinical trial sites span multiple regions including North America, with investigators at academic medical centres in New Hampshire, Ontario Canada, and other locations contributing to enrollment. Bausch Health Canada and other pharmaceutical companies based in Ontario Canada have also invested in adjacent metabolic disease areas. The N Engl J Med and Lancet Diabetes Endocrinol continue to serve as primary publication venues for obesity trials conducted across these international networks, with compared with placebo results reported for all active treatment arms.

Both compounds engage glucagon receptor signaling, but retatrutide adds GIP receptor agonism as a third pathway. Survodutide’s strongest differentiating narrative today is the explicit, FDA-designated MASH development programme. For a mechanistic deep dive into how these receptors interact, see our explainer on the triple agonist GIP, GLP-1, and glucagon pathway.